Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 1/20 | 0.47 |
| ▸ | PIK3CD | O00329 | 14/20 | 0.41 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.41 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.41 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CNR2 | P34972 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2674526 | 0.85 | HDAC1 (0.46) | HDAC1PIK3CDPIK3CGPIK3CBPIK3CA | |
| SCHEMBL2673595 | 0.84 | HDAC1 (0.47) | HDAC1PIK3CDPIK3CGPIK3CBPIK3CA | |
| SCHEMBL2675207 | 0.83 | HDAC1 (0.46) | HDAC1PIK3CDPIK3CGPIK3CBPIK3CA | |
| SCHEMBL2673534 | 0.81 | HDAC1 (0.47) | HDAC1PIK3CDPIK3CGPIK3CBPIK3CA | |
| SCHEMBL2674439 | 0.81 | HDAC1 (0.55) | HDAC1PIK3CDPIK3CGPIK3CBPIK3CA | |
| SCHEMBL2673725 | 0.81 | HDAC1 (0.49) | HDAC1PIK3CDPIK3CGPIK3CBPIK3CA | |
| SCHEMBL2673978 | 0.81 | PIK3CD (0.50) | HDAC1PIK3CDPIK3CGPIK3CBPIK3CA | |
| SCHEMBL2674202 | 0.81 | PIK3CD (0.50) | HDAC1PIK3CDPIK3CGPIK3CBPIK3CA | |
| SCHEMBL2674604 | 0.81 | HDAC1 (0.48) | HDAC1PIK3CDPIK3CGPIK3CBPIK3CA | |
| SCHEMBL2674788 | 0.81 | HDAC1 (0.48) | HDAC1PIK3CDPIK3CGPIK3CBPIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8394796-B2 | Bicyclic pyrimidine PI3K inhibitor compounds selective for P110 delta, and methods of use | GENENTECH, INC. (US) | 2013-03-12 | — | — | US | disclosed |
| US-20120178736-A1 | BICYCLIC PYRIMIDINE PI3K INHIBITOR COMPOUNDS SELECTIVE FOR P110 DELTA, AND METHODS OF USE | CASTANEDO GEORGETTE (US) | 2012-07-12 | — | — | US | disclosed |
| US-8173650-B2 | Bicyclic pyrimidine PI3K inhibitor compounds selective for P110 delta, and methods of use | GENENTECH, INC. (US) | 2012-05-08 | — | — | US | disclosed |
| WO-2010138589-A1 | BICYCLIC PYRIMIDINE PI3K INHIBITOR COMPOUNDS SELECTIVE FOR P110 DELTA, AND METHODS OF USE | GENENTECH, INC. (US) | 2010-12-02 | — | — | WO | disclosed |
| US-20100305096-A1 | BICYCLIC PYRIMIDINE PI3K INHIBITOR COMPOUNDS SELECTIVE FOR P110 DELTA, AND METHODS OF USE | GENENTECH, INC. | 2010-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120178736-A1 | BICYCLIC PYRIMIDINE PI3K INHIBITOR COMPOUNDS SELECTIVE FOR P110 DELTA, AND METHODS OF USE | PIK3CA, PIK3R2, PIK3CD | HDAC1 2190/4885PIK3CD 3/4885PIK3CG 11/4885 |
| US-20100305096-A1 | BICYCLIC PYRIMIDINE PI3K INHIBITOR COMPOUNDS SELECTIVE FOR P110 DELTA, AND METHODS OF USE | PIK3CA, PIK3R2, PIK3CD | HDAC1 2194/4885PIK3CD 3/4885PIK3CG 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.